Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oncology/Acute Myeloid Leukemia

Acute Myeloid Leukemia

254

Pipeline Programs↗

385

Active Trials↗

148

Companies Involved↗

Acute Myeloid Leukemia is a highly competitive landscape with 254 programs across 148 companies. The most active players are Lomond Therapeutics Holdings, Inc., Takeda, Institut de Recherches Internationales Servier. 44 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

91/100

Pipeline Velocity

88/100

Mech. Concentration

8/100

Completion Rate

66/100

Attrition Rate

19/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Lomond Therapeutics Holdings, Inc.

4 programs

Takeda

2 programs

Institut de Recherches Internationales Servier

2 programs

Actinium Pharmaceuticals

1 program

Johnson & Johnson

1 program

Ascentage Pharma Group Inc.

1 program

Pipeline

Programs by Phase

Preclinical38

EP0042

Ellipses Pharma

Chemotherapy Drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Antibiotic

Pfizer

Patients With Antifungal Prophylaxis

University Hospital, Brest

Atra+venetoclax+azacitidine

The First Affiliated Hospital of Soochow University

Phase 190

Cobimetinib

Roche

ORCA-T

Orca Biosystems, Inc.

Etoposide Phosphate

German Society for Pediatric Oncology and Hematology GPOH gGmbH

Crd3874-Si

Memorial Sloan Kettering Cancer Center

Orcagraft (orca-Q)

Orca Biosystems, Inc.

Phase 282

Dasatinib

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Carboplatin

Avyxa

Metformin

EMD Serono

Topotecan Hydrochloride

Meitheal

Cladribine

EMD Serono

Phase 344

Mitoxantrone Hydrochloride

Pfizer

Mitoxantrone

EMD Serono

Pevonedistat

Takeda

Mycophenolate Mofetil

Roche

Melphalan

Apotex Inc.

Approved

No programs

Analysis

Modality Breakdown

76%

Small molecule

173 of 229 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 229 classified programs, each share of the total. Modality classified for 95% of 254 pipeline programs.

Analysis

Trial Status

1,129

clinical trials

Completed421 · 37%

Recruiting225 · 20%

Terminated163 · 14%

Unknown status99 · 9%

Active, not recruiting96 · 9%

Not yet recruiting59 · 5%

Other66 · 6%

Clinical Trials

Trial Activity

1129 trials

A Multicenter, Open-Label, Dose-Finding Clinical Trial to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Efficacy of RVU120 in Combination With Venetoclax in Participants With Acute Myeloid Leukemia Who Failed Prior Therapy With Ventoclax and a Hypomethylating Agent

Recruiting·RRyvu Therapeutics SA·Phase 2·NCT06191263·98 enrolled

A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

Recruiting·MM.D. Anderson Cancer Center·Preclinical·NCT06284486·8 enrolled

Phase 1 Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06769490·44 enrolled

A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults With Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Substudy

Recruiting·National Cancer Institute (NCI)·Phase 2·NCT06317649·147 enrolled

A Measurable Residual Disease (MRD) Focused, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients With Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH SubStudy

Recruiting·National Cancer Institute (NCI)·Phase 2·NCT05554393·153 enrolled

A Phase 2 Study of Fludarabine, Cytarabine, Filgrastim-sndz,Gemtuzumab Ozogamicin and Idarubicin in Newly Diagnosed Core Binding Factor Associated Acute Myelogenous Leukemia

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT00801489·270 enrolled

A Randomized Phase II Trial of ASTX727 and Venetoclax Compared With ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults With IDH2 Mutant Acute Myeloid Leukemia: A MyeloMATCH Substudy

Recruiting·National Cancer Institute (NCI)·Phase 2·NCT06672146·93 enrolled

Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials

Recruiting·National Cancer Institute (NCI)·Phase 2·NCT05564390·2,000 enrolled

Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Therapy

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT03630991·58 enrolled

A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who Are Considered High-Risk (Adverse) Acute Myeloid Leukemia As Determined by MYELOMATCH; A MYELOMATCH SubStudy

Recruiting·National Cancer Institute (NCI)·Phase 2·NCT05554406·335 enrolled

A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations

Recruiting·Children's Oncology Group·Phase 3·NCT04293562·1,400 enrolled

A Randomized Phase III, Global, Multicentre, Open Label Clinical Trial Comparing Venetoclax Azacytidine and Quizartinib Versus Venetoclax and Azacytidine in Newly Diagnosed Acute Myeloid Leukemia Patients Unelegible for Standard Induction Chemotherapy

Recruiting·PPETHEMA Foundation·Phase 3·NCT07478991·376 enrolled

CLAG-M or FLAG-Ida Chemotherapy Followed Immediately by Related/Unrelated Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Cell Transplantation for Adults With Myeloid Malignancies at High Risk of Relapse: A Phase 1 Study

Recruiting·FFred Hutchinson Cancer Center·Phase 1·NCT04375631·120 enrolled

A Collaboration Phase 2 Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia

Recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT05955261·70 enrolled

A Phase 2 Trial Investigating Decitabine in Combination With a JAK-Inhibitor as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant in Patients With Accelerated/Blast Phase Myeloproliferative Neoplasms

Recruiting·UUniversity of Washington·Phase 2·NCT04282187·25 enrolled

Page 1 of 76

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)